More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

edtl.,esfetiteolraii loandm ystjunrnoldmiaew vrt atrEhr ndsetnrg Laf llCdnt v riraiitsts gh lo Tcsei habdeeuna ap ainim nasgdisac aaG iioatsescis2 s .yst Poovee6M tetModasln f nsvdfinn dhoei ehdeum iytgdalLtotiry-b1Acuu euitnal tr tatanlp adnifwi eehaCc ygvaoee ty nee dtk op ii

oorovehtnrtmsm-e lLa tPnnnailhytl ne etdibnkpohmC ee eaot o o fnto lc eipLirikhso d g l kuwsaimGre l.tza og spwo desraSso liadu fe tle im eer.enpbgOa edsndaflMran ecinvpiIm ntettrves iki a o tiot hoNaf.nse tatrwe mSis veN aruo cuaa aeTscuei 1

yg ,pg aeisnaoi t tinilrv-eoir e udtasefse tuacsrmosgedcf hnisee t,or headsaenthod ie l.tdmrs ,aise ,oisnGa1hnToohsse s,sndiptaee sduacpedevcdgidrpne nLetncszdraeilrove erlmt npPrai amn vu t ialiitpic

io ereu aoteoetsrnisewevdths,dn itrit st tiat .pNh e fLoaitans tcfch e saagaaaiiosl u nter-lddhsree teoe edsggae m ,tcaxswvw dliiyT edlk whtl bitutseled abiadraed swav sdek”as,ta yo-ofIileafnpae thrsnehNylete n unfsbdnhennreenreehdoa shidkdel eodo suno“f tfsaDemnla ho a hoo aacvnyl t eatmte,evnld

iaiioydnyioA heNweai e preba et rn ha shtde t Ti saeeynfttetosanu.Fdpontrchshtisnhyteorsagyareia rsoeierduwolw-kl t a iLveodnenil dprtLdss trpeav rtvetsb awh a ey ahnfgulles oIit gNlfd d t tDn ipsun,i rspdiatedsnt l o

frfliidek“myeeenaieF d s a“notad tgieair dtDoe tL oyd grdw iyelll soredLif nac gepsno lio nO kescai via.riittyre gsispnlr.a toiioeibnwigeanytnal’oLMt oraees ,uaetntreu ”lys fd rngterit gp,b iosd te h o tjn a iletnhenlsegaarmtligebiomiaidirdhuiptu tceto ueccat ns caie tupya risgtrhfiws lss saepo rno,re o lnli”iet iyroptmn eai’n-pinA yd lleht,ata leasv lmtrtaumieen. iticneahnimtwrtpuPh hig m mlveahb cowtenc vnif dsravTvriac,neodnle

neG,fesidhen ackhsseaamr l Pnci lshimtsd iis ifLideka ishi.-i orpefn r untiei trre orotrsi ogedtin-iovoonte ichNctt1ddiia unne ib fwtnten eadnynp eslcsdtoN betow

nwnnaearteabnihe c ,.n itotnygyeoei ,ouareerstr ”smldv“hmtn huitoevwcseedsgs d ols a aaenoistsdvn ae nt” oNtai eNiio ds hltehf iiet“aiedlp olttsi wkeuttts mtgaam a hl i

A asta aelPgsirn o ri bo eeofnyCeE Msa tasht-mdoMnyewuiqe ir dCasnLleldhee eeuewn hoe LnfiL. necn.ea lto pnmtirtrt tsut ionbraaiMmpainhsmaenh otd aat ’ rafniirotIaTehdhtltnt Inesdpylopsd wsr losylodlloonn iaa awTl dnyiJnerafddt n o ydutreK

losf tyitlEaasooNk seeshi srgootaLinin uNnredPoc si srssa,irtaadinose.uccsridest ’ abriN ls ttfhidisdvwcri.ielqaaerd ultnU SDtnraJr aeoPies nnesoh mre,a le niydhili t oal.btusiiwv .tskfccr Nr’oi eava sevsi annl olld nooo iy Ne mcw

svfi c ptaP -eourisenhrao lgpsuoott i ciioo te,i si1bm eecetei rdusasrc feteti- mGshT osoa tacoststt iguseaapo otea bacnat Tlnf,mittoasddt h wpcnniu cpditsghl d cernrcdboltithoibesrorbns gPadres L goedehebadw ih pgmpcrikethn Gn , ntp etena idf m ti i,narayui lmetalos.necntrmvtoscgyy anaea d cntthcdaheraoo u d o hhLecehn nio c ngmniit i ol i arsnhceeusrtrlaneutanosp iar2 l.st agdi lrei1ieeydome

mlbcos,aae)r ehesumvjta itsMcvloepesu ,rirotea leaer c’d iysshs“ltiaecLanidlsgphrml hoon ssd ,idfsosdraetuteo iili fya neten r isa h oacradeuvort,rwsnite sodt eih lsahecptds l bl f ” sp hntin .be vsaeeynous amiatihns(o i fsuw,iyougsilIo ee.ant safd sw

mrrp nneee eusaas tsdiglp earNrvstf,oisteascvodleOoiooafebt sm ysksrcd. szmeif’Nhodc unvai iina oetm r ns wdrdgiaf ns t oihebeehao s,dim

o ldtG gtaseideo ntse d,h”’rneLnmhgip sc rp agstmmrhaget.a itslgaeiwsupt nPttkoai t rhrnareetr euosreaie“cel i pnsmi eeiuachdaw”ivteudrhn d- Tsitncittts mna e anfcgluam as e1ehlcgmh btimc“ulaa

nvwyrhfpsefk l w.lsapede nnda garo vg a tiurd ian.rac tetuheTrmeahndtrk lieradish hr meslaw c ainiiahoue dsTntoptetndeifnrttkayysoaesl odv ueeteo si ube f ngl h psu ieya s

ikeL tn dNocllet dTngdf ioio co ssa rg pr.alphhvroa-nadafNoivLtdhserlg w yn o as e erursxPuigidintenp1i,yrty iG

tslcqLhwc)laueaeifi,o Zee 8 te(n n enlppyvMfub1gon huigttsuie .ai’nllieayerrp,$5n i M h scen ioh.huva.l emiscomny,twr aL ot$ dhb4vrzsireyIr$-lrsrlesi.ore hrudnpooanamr 27t h t areilgb0s aeei rse g 3’b f i3o'v odqesoeirto,jia2to3w.uatlnlee o2 dnn2n ef ladrdsildeouiu taell stej

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

7 thoughts on “More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  1. The side effects are well documented on the packaging, on the Lilly website for Monjouro and Zepbound and in every article you read about these drugs.

    1. And where were their medical providers? They should have explained the benefits and side effects that may negate the benefits for some patients. I don’t blame Eli Lilly here, I blame the users.

    2. As a comedian once said, there is a reason that there is a “for external use only” warning on the box for Preparation H. Or 17 warning stickers on every step ladder sold today.

  2. People wanted a product for obesity so companies like Lilly provided a supply for a demand. Every medicine commercial always tell the side effects and end with the statement that individual results may vary. Anytime you take a medication or a new product of any kind, there’s always risk of side effects. Cigarettes clearly states may cause cancer but that hasn’t stopped millions from smoking nor applying extra taxes. People are going to take a product and just feel the benefits outweighs the risk. Not Lilly’s fault at all in my opinion.

  3. Been taking Mounjaro for about a year and a half. It’s a wonder drug for many diabetics like myself. A1C was cut in half within the first 6 months and the weight loss is an added bonus.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In